Rachel Schiff

24.3k citations

171 papers · 15.1k indexed · 6 hit papers · h-index 66

Oncology top 0.1%
Molecular Biology top 0.5%
Genetics top 0.1%
Cancer Research top 0.2%
Pulmonary and Respiratory Medicine top 0.5%

Co-authors: C. Kent Osborne Suleiman Massarweh Jiang Shou Grazia Arpino Mothaffar F. Rimawi Carolina Gutiérrez Susan G. Hilsenbeck Carmine De Angelis
Topics: HER2/EGFR in Cancer Research (85 papers)Estrogen and related hormone effects (66 papers)Monoclonal and Polyclonal Antibodies Research (32 papers)
Cited by: Oncology Cancer Research Genetics
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Biological Chemistry
Partner nations: United States Italy Switzerland

In The Last Decade

Rachel Schiff

169 papers receiving 14.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

2004 918 citations Suleiman Massarweh, Rachel Schiff et al. profile →
Mechanisms of Endocrine Resistance in Breast Cancer

2010 877 citations C. Kent Osborne, Rachel Schiff Annual Review of Medicine profile →
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes

1998 550 citations Rachel Schiff, Susan G. Hilsenbeck et al. profile →
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo

2011 473 citations Xiaoyong Fu, Rachel Schiff et al. profile →
HER2: Biology, Detection, and Clinical Implications

2011 456 citations Carolina Gutiérrez, Rachel Schiff profile →
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

2015 454 citations Rinath Jeselsohn, Carmine De Angelis et al. profile →

Peers

Countries citing papers authored by Rachel Schiff

Since Specialization

Citations

This map shows the geographic impact of Rachel Schiff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Schiff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Schiff more than expected).

Fields of papers citing papers by Rachel Schiff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Schiff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Schiff. The network helps show where Rachel Schiff may publish in the future.

Co-authorship network of co-authors of Rachel Schiff

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Schiff. A scholar is included among the top collaborators of Rachel Schiff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Schiff. Rachel Schiff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer 2021 ·Clinical Cancer Research ·Xian Wang,Jamunarani Veeraraghavan,(unknown),(unknown),Lanfang Qin,Jin-Ah Kim,Ying Tan,(unknown),Yiheng Hu,Ling Lin,Sanghoon Lee,Martin J. Shea,Tamika Mitchell,Shunqiang Li,Matthew J. Ellis,Susan G. Hilsenbeck,Rachel Schiff,Xiao-Song Wang	8
2	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize 2018 ·Cancer Research ·Mario Giuliano,(unknown),Hin Ching Lo,Grazia Arpino,Sabino De Placido,Xiang H.-F. Zhang,Massimo Cristofanilli,Rachel Schiff,Meghana V. Trivedi	153
3	Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition 2018 ·Molecular Cancer Therapeutics ·(unknown),Zhuo Zhang,Rajani Rajbhandari,Tiffiny S. Cooper,Ling Zeng,Andres Forero,Francisco J. Esteva,C. Kent Osborne,Rachel Schiff,Albert F. LoBuglio,Susan E. Nozell,Eddy S. Yang	14
4	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis 2017 ·Cancer Research ·Yanming Wu,Zhao Zhang,(unknown),Cecilia J. Proietti,(unknown),Tao Hong,Mei Yang,Yiji Liao,Huai-Chin Chiang,Virginia Kaklamani,Rinath Jeselsohn,Ratna K. Vadlamudi,Tim H.‐M. Huang,Rong Li,Carmine De Angelis,Xiaoyong Fu,Patricia V. Elizalde,Rachel Schiff,Myles Brown,Kexin Xu	80
5	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance 2016 ·Molecular Cancer Research ·Luca Malorni,Mario Giuliano,Ilenia Migliaccio,Tao Wang,Chad J. Creighton,Mathieu Lupien,Xiaoyong Fu,Susan G. Hilsenbeck,Nuala Healy,Carmine De Angelis,Abhijit Mazumdar,Meghana V. Trivedi,Suleiman Massarweh,Carolina Gutiérrez,Sabino De Placido,Rinath Jeselsohn,Myles Brown,Powel H. Brown,C. Kent Osborne,Rachel Schiff	31
6	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes 2016 ·Cancer Research ·Andriy Marusyk,Doris P. Tabassum,Michalina Janiszewska,Andrew E. Place,Anne Trinh,Andrii I. Rozhok,Saumyadipta Pyne,Jennifer L. Guerriero,Shaokun Shu,Muhammad B. Ekram,(unknown),Daniel P. Cahill,Yuri Nikolsky,Timothy A. Chan,Mothaffar F. Rimawi,Susan G. Hilsenbeck,Rachel Schiff,Kent C. Osborne,Antony Letai,Kornélia Polyák	96
7	Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint 2016 ·Molecular Cancer Research ·Jinah Kim,Meenakshi Anurag,Jamunarani Veeraraghavan,Rachel Schiff,Kaiyi Li,Xiao‐Song Wang	22
8	Targeting HER2 for the Treatment of Breast Cancer 2015 ·Annual Review of Medicine ·Mothaffar F. Rimawi,Rachel Schiff,C. Kent Osborne	208
9	Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer 2015 ·Clinical Breast Cancer ·Alice Chung,Michael Choi,(unknown),Shikha Bose,Xiao Zhang,Lali K. Medina‐Kauwe,Jessica Sims,Ramachandran Murali,(unknown),(unknown),Rachel Schiff,Armando E. Giuliano,Xiaojiang Cui	9
10	Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance 2014 ·Breast Cancer Research and Treatment ·Gladys Morrison,Xiaoyong Fu,Martin J. Shea,Sarmistha Nanda,Mario Giuliano,Tao Wang,Teresa Klinowska,C. Kent Osborne,Mothaffar F. Rimawi,Rachel Schiff	39
11	Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer 2013 ·The Breast ·Xiaoyong Fu,C. Kent Osborne,Rachel Schiff	64
12	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 2013 ·Journal of Clinical Oncology ·Mothaffar F. Rimawi,Ingrid A. Mayer,Andres Forero,Rita Nanda,Matthew P. Goetz,Angel Rodriguez,Anne C. Pavlick,Tao Wang,Susan G. Hilsenbeck,Carolina Gutiérrez,Rachel Schiff,C. Kent Osborne,Jenny C. Chang	187
13	Cytoplasmic Estrogen Receptor in Breast Cancer 2011 ·Clinical Cancer Research ·Allison W. Welsh,Donald R. Lannin,Gregory Young,Mark E. Sherman,Jonine D. Figueroa,N. Lynn Henry,Lisa Rydén,Chungyeul Kim,Richard R. Love,Rachel Schiff,David L. Rimm	49
14	A Noncompetitive Small Molecule Inhibitor of Estrogen-regulated Gene Expression and Breast Cancer Cell Growth That Enhances Proteasome-dependent Degradation of Estrogen Receptor α 2010 ·Journal of Biological Chemistry ·Nicole M. Kretzer,Milu T. Cherian,Chengjian Mao,Irene O. Aninye,Philip D. Reynolds,Rachel Schiff,Paul J. Hergenrother,Steven K. Nordeen,Elizabeth M. Wilson,David J. Shapiro	18
15	Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts 2010 ·Clinical Cancer Research ·Mothaffar F. Rimawi,Lisa Wiechmann,Yen-Chao Wang,Catherine Huang,Ilenia Migliaccio,Meng-Fen Wu,Carolina Gutiérrez,Susan G. Hilsenbeck,Grazia Arpino,Suleiman Massarweh,(unknown),(unknown),C. Kent Osborne,Rachel Schiff	66
16	Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function 2008 ·Cancer Research ·Suleiman Massarweh,C. Kent Osborne,Chad J. Creighton,Lanfang Qin,Anna Tsimelzon,Shixia Huang,Heidi L. Weiss,Mothaffar F. Rimawi,Rachel Schiff	375
17	Dual Roles for Coactivator Activator and its Counterbalancing Isoform Coactivator Modulator in Human Kidney Cell Tumorigenesis 2008 ·Cancer Research ·Yun Kyoung Kang,Rachel Schiff,Lan Ko,Tao Wang,Sophia Y. Tsai,Ming‐Jer Tsai,Bert W. O’Malley	20
18	Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts 2008 ·Cancer Research ·Chad J. Creighton,Suleiman Massarweh,Shixia Huang,Anna Tsimelzon,Susan G. Hilsenbeck,C. Kent Osborne,Jiang Shou,Luca Malorni,Rachel Schiff	101
19	Estrogen Dendrimer Conjugates that Preferentially Activate Extranuclear, Nongenomic Versus Genomic Pathways of Estrogen Action 2005 ·Molecular Endocrinology ·(unknown),Sung Hoon Kim,Cory C. Funk,Zeynep Madak‐Erdogan,Rachel Schiff,John A. Katzenellenbogen,Benita S. Katzenellenbogen	211
20	Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. 2003 ·PubMed ·Rachel Schiff,Suleiman Massarweh,Jiang Shou,C. Kent Osborne	250

About Rachel Schiff

Rachel Schiff is a scholar working on Oncology, Genetics and Cancer Research, having authored 171 papers that have together received 15.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (85 papers), Estrogen and related hormone effects (66 papers) and Monoclonal and Polyclonal Antibodies Research (32 papers). The work is most often cited by research in Oncology (7.9k citations), Cancer Research (3.8k citations) and Genetics (4.9k citations). Rachel Schiff has collaborated with scholars based in United States, Italy and Switzerland. Frequent co-authors include C. Kent Osborne, Suleiman Massarweh, Jiang Shou, Grazia Arpino, Mothaffar F. Rimawi, Carolina Gutiérrez, Susan G. Hilsenbeck, Carmine De Angelis, Adrian V. Lee and C. Kent Osborne. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact